The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10‐year follow‐up)

Virno, M; Pecori-Giraldi, J; Liguori, Antonio; Gregorio, Fabio De

doi:10.1111/j.1600-0420.2000.tb01107.x

Cited by 41 publications

(43 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a long-term study from the same author [27], such a positive effect could be demonstrated during 8 years of follow-up. In another long-term study the positive effect of citicoline could be shown on visual field changes [28]. The mechanism of action of citicoline is intricate and subtle.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, a beneficial effect of citicoline has been described in a number of conditions affecting the visual system, like amblyopia [21,22,23,24] and nonarteritic ischemic optic neuropathy [25]. There are interesting findings concerning the use of citicoline in glaucoma [26,27,28,29,30,31]. In particular, in a double-blind placebo-controlled study with glaucoma patients, citicoline given by intramuscular injections for 60 consecutive days has been found to shorten the visual evoked potential P100 latency and increase the N75-P100 amplitude [26].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Citicoline Oral Solution in Glaucoma: Is There a Role in Slowing Disease Progression?

et al. 2013

View full text Add to dashboard Cite

Purpose: To assess the effect of citicoline on visual field rates of progression in patients with progressing glaucoma. Patients and Methods: Forty-one patients with a diagnosis of progressing glaucoma received citicoline in oral solution for 2 years. Included were patients with a disease progression of at least -1 dB/year (at MD, mean deviation) for at least 3 years before entering the study despite controlled intraocular pressure (IOP). Patients were followed with 4 visual field examinations per year for 2 years. Results: At baseline, the mean rate of progression was -1.1 (±0.7) dB/year despite the fact that the IOP had been below 18 mm Hg for at least 3 years. At study inclusion, the mean IOP was 15.5 (±2.6) mm Hg and the mean MD was -9.2 (±6.7) dB in the worst eye. Starting from the first cycle of treatment with citicoline, the mean rate of progression significantly changed to -0.15 (±0.3) dB/year at the end of the study (p = 0.01). Conclusions: This study seems to indicate that supplementation with citicoline might significantly slow down glaucomatous rates of progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Citicoline Oral Solution in Glaucoma: Is There a Role in Slowing Disease Progression?

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Although none of the recent reviews on citicoline (Weiss, 1995;Secades and Frontera, 1995;D'Orlando and Sandage, 1995) mentioned its possible application for treatment of glaucoma, a few clinical trials reported to date ahve indicated some benefits of such treatment (Pecori Giraldi et al, 1989;Parisi et al, 1999;Virno et al, 2000). The aim of the present review is to provide a rationale for further development of this drug for glaucoma treatment.…”

mentioning

confidence: 89%

“…Although the evidence for beneficial effects of citicoline in glaucoma is sparse, results of two long-term, open trials have been suggestive that this drug acts positively on the glaucomatous optic nerve damage as assessed perimetrically (Pecori Giraldi et al, 1989;Virno et al, 2000), and one short-term, placebo-controlled study indicated that such a treatment leads to functional improvement in both retinal and suprartetinal pathways (Parisi et al, 1999). Although these observations are not yet sufficient for the introduction of citicoline in standard therapy for glaucoma, they nicely correspond with welldocumented neuroprotective and dopamine-enhancing properties of the drug at the brain level.…”

Section: Concluding Commentsmentioning

confidence: 99%

Pharmacodynamics of citicoline relevant to the treatment of glaucoma

Grieb

Ręjdak

2001

J of Neuroscience Research

View full text Add to dashboard Cite

Citicoline (exogenous CDP‐choline) is a nontoxic and well‐tolerated drug used in pharmacotherapy of brain insufficiency and some other neurological disorders, such as stroke, brain trauma, and Parkinson's disease. A few reports indicate that citicoline treatment may also be beneficial in glaucoma. Currently glaucoma is considered a neurodegenerative disease in which retinal ganglion cells (RGC) slowly die, likely in the apoptotic mechanism. Endogenous CDP‐choline is a natural precursor of cellular synthesis of phospholipids, mainly phosphatydylcholine (PtdCho). Enhancement of PtdCho synthesis may counteract neuronal apoptosis and provide neuroprotection. Citicoline, when administered, undergoes a quick transformation to cytidine and choline, which are believed to enter brain cells separately and provide neuroprotection by enhancing PtdCho synthesis; similar effect may be expected to occur in glaucomatous RGC. Furthermore, citicoline stimulates some brain neurotransmitter systems, including the dopaminergic system, and dopamine is known as a major neurotransmitter in retina and postretinal visual pathways. In a double‐blind, placebo‐controlled study, treatment of glaucoma resulted in functional improvement in the visual system noted with electrophysiological methods. Development of citicoline as a treatment for glaucoma is indicated. © 2002 Wiley‐Liss, Inc.

show abstract

“…Four publications reported on studies in which CDP-choline was administered via intramuscular injection (Pecori Giraldi at al., 1989;Parisi et al, 1999Parisi et al, , 2005Virno et al, 2000). The Panel notes that parenteral routes of administration are not relevant to the assessment of health claims made on food and considers that these studies do not provide evidence for the scientific substantiation of a claim on dietary CDP-choline.…”

Section: Scientific Substantiation Of the Claimed Effectmentioning

confidence: 99%

Scientific Opinion on the substantiation of a health claim related to cytidine 5‐diphosphocholine and maintenance of normal vision pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Products¹

2014

EFS2

View full text Add to dashboard Cite

Following an application from Omikron Italia S.r.l. submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924No /2006 via the Competent Authority of Italy, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to cytidine 5 -diphosphocholine and maintenance of normal vision. The Panel considers that the food constituent cytidine 5 -diphosphocholine (CDP-choline or citicoline), which is the subject of the health claim, is sufficiently characterised. The claimed effect, maintenance of normal vision, is a beneficial physiological effect. The Panel considers that no conclusions can be drawn from the three narrative reviews and the eight human intervention studies provided by the applicant for the scientific substantiation of the claim. The Panel concludes that a cause and effect relationship has not been established between the consumption of CDP-choline and maintenance of normal vision. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. The application included a request for the protection of proprietary data.The food constituent that is the subject of the health claim is cytidine 5 -diphosphocholine (CDP-choline or citicoline). The Panel considers that the food constituent CDP-choline, which is the subject of the health claim, is sufficiently characterisedThe claimed effect proposed by the applicant relates to maintenance (or reduced loss) of normal vision. The target population proposed by the applicant is "elderly subjects since middle age". The Panel considers that maintenance of normal vision is a beneficial physiological effect.The applicant identified eight human intervention studies, three reviews, and three non-human studies as being pertinent to the health claim.The narrative reviews referred to the pharmacological proprieties of CDP-choline, and to the treatment of glaucoma. Four publications reported on studies in which CDP-choline was administered via intramuscular injection, which is a route of administration that is not relevant to the assessment of health claims made on food. The Panel considers that no conclusions can be drawn from these references for the scientific substantiation of the claim.The remaining four human intervention studies investigated the effect of oral administration of CDP-choline on several outcome measures in subjects with glaucoma or with non-arteritic ischaemic optic neuropathy.During the evaluation process, the applicant was requested to clarify how results obtained in subjects with presumed damage to the retinal ganglion cells and/or optic nerve owing to glaucoma or to an ischaemic event could be extrapolated to the target population (i.e. healthy subjects without damaged retinal ganglion cells or optic nerve) for which the claim is made. The Panel notes that no evidence, which could justify the extrapolation of the results obtained in patients with glaucom...

show abstract

The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10‐year follow‐up)

Cited by 41 publications

References 6 publications

Citicoline Oral Solution in Glaucoma: Is There a Role in Slowing Disease Progression?

Citicoline Oral Solution in Glaucoma: Is There a Role in Slowing Disease Progression?

Pharmacodynamics of citicoline relevant to the treatment of glaucoma

Scientific Opinion on the substantiation of a health claim related to cytidine 5‐diphosphocholine and maintenance of normal vision pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Contact Info

Product

Resources

About